Caprolactam Chem

Which are the latest news on Caprolactam Chem?

Why is Caprolactam Chemicals Ltd falling/rising?

As of 26-Jul, Caprolactam Chemicals Ltd's stock price is slightly declining at 49.82, despite outperforming its sector today. While it has shown positive long-term performance, recent volatility and mixed signals from moving averages suggest cautious investor sentiment.

As of 26-Jul, Caprolactam Chemicals Ltd's stock price is experiencing a slight decline, currently at 49.82, reflecting a change of -0.01 (-0.02%). This minor decrease occurs despite the stock outperforming its sector by 0.39% today. Over the past week, the stock has shown a minimal decline of -0.04%, while the broader market, represented by the Sensex, has decreased by -2.68%. <BR><BR>In the longer term, the stock has performed positively over the past month, with a gain of +7.84%, contrasting with the Sensex's drop of -1.21%. Year-to-date, however, Caprolactam Chemicals Ltd has seen a decline of -4.34%, which is better than the Sensex's -10.75% drop. Over the past year, the stock has risen by +18.62%, significantly outperforming the Sensex, which has fallen by -7.45%.<BR><BR>Despite these positive trends, the stock has faced erratic trading, not trading on 3 out of the last 20 days, which may contribute to its current price volatility. Additionally, while the stock's moving averages are higher than the 5-day, 20-day, 50-day, and 200-day averages, they remain lower than the 100-day moving average, indicating mixed signals regarding its price momentum. <BR><BR>Investor participation appears to be increasing, as evidenced by a 22.71% rise in delivery volume on July 17 compared to the 5-day average. This suggests a growing interest in the stock, which could support future price stability or growth. However, the current liquidity indicates that the stock is liquid enough for trading, which may help mitigate further declines. Overall, while there are positive indicators, the slight decline in price today reflects a complex interplay of market conditions and trading behavior.

Should I buy, sell or hold Caprolactam Chemicals Ltd?

How big is Caprolactam Chem?

As of 10th June, Caprolactam Chemicals Ltd has a market capitalization of 23.00 Cr, with recent net sales of 10.55 Cr and a net profit of 1.77 Cr. Shareholder's funds are 4.83 Cr, and total assets amount to 14.28 Cr.

As of 10th June, Caprolactam Chemicals Ltd has a market capitalization of 23.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest 4 quarters, the company reported Net Sales of 10.55 Cr and a Net Profit of 1.77 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 4.83 Cr and Total Assets of 14.28 Cr.

Who are in the management team of Caprolactam Chem?

The management team of Caprolactam Chem includes Z S Bhanushali (Chairperson & Managing Director), S S Bhanushali (Whole Time Director & CFO), and independent directors V P Adagale, R P Mange, and Poonam Bhavin Bhanushali, along with Dolly Dipesh Shah as Company Secretary & Compliance Officer.

The management team of Caprolactam Chem includes the following individuals:<BR><BR>1. **Z S Bhanushali** - Chairperson & Managing Director<BR>2. **S S Bhanushali** - Whole Time Director & Chief Financial Officer<BR>3. **V P Adagale** - Independent Director<BR>4. **R P Mange** - Independent Director<BR>5. **Poonam Bhavin Bhanushali** - Independent Director<BR>6. **Dolly Dipesh Shah** - Company Secretary & Compliance Officer<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

Who are the peers of the Caprolactam Chem?

Caprolactam Chem's peers include Advance Petrochem, Vinyoflex, Deco-Mica, Pentokey Organy, Tulasee Bio-Eth, Jayshree Chem, Omkar Pharmachem, and Vivid Global. Key insights show Vinyoflex has excellent management risk, while Caprolactam Chem has below average growth and capital structure, with a 1-year return of 17.25%.

Peers: The peers of Caprolactam Chem are Advance Petroch., Vinyoflex, Deco-Mica, Pentokey Organy, Tulasee Bio-Eth., Square Four Pro., Jayshree Chem., Omkar Pharmachem, and Vivid Global.<BR><BR>Quality Snapshot: Excellent management risk is observed at Vinyoflex, while Average management risk is found at Advance Petroch., and Jayshree Chem. Below Average management risk is noted at Deco-Mica, Pentokey Organy, Caprolactam Chem, and Vivid Global, and the rest. Growth ratings show that Average growth is present at Jayshree Chem, while Below Average growth is seen at Advance Petroch., Vinyoflex, Deco-Mica, Pentokey Organy, Caprolactam Chem, and the rest. Capital Structure ratings indicate Good capital structure at Vinyoflex and Pentokey Organy, while Below Average capital structure is found at Advance Petroch., Deco-Mica, Caprolactam Chem, Jayshree Chem, and Vivid Global, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Tulasee Bio-Eth. at 127.58%, while the lowest is Deco-Mica at -27.25%. Caprolactam Chem's own 1-year return of 17.25% is higher than that of Deco-Mica but lower than Tulasee Bio-Eth. Additionally, peers such as Pentokey Organy, Omkar Pharmachem, and Deco-Mica have negative six-month returns.

What does Caprolactam Chem do?

Caprolactam Chemicals Ltd is a micro-cap company in the commodity chemicals industry, reporting net sales of 3 Cr and a net profit of 1 Cr as of March 2026. The company has a market cap of INR 23 Cr and a P/E ratio of 13.00.

Overview: <BR>Caprolactam Chemicals Ltd operates in the commodity chemicals industry and is classified as a micro-cap company.<BR><BR>History: <BR>The company was incorporated in November 1988 and was registered as a sick company by the Board of Industrial and Finance Reconstruction (BIFR) in 2001. As of the latest quarterly results for March 2026, the company reported a positive net worth and has since been deregistered from the purview of SICA/BIFR.<BR><BR>Financial Snapshot: <BR>Net Sales: 3 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 23 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 13.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 1.68 <BR>Return on Equity: 33.27% <BR>Price to Book: 4.24 <BR><BR>Contact Details: <BR>Address: B/31 MIDC Industrial Area, Taluka - Mahad Raigad Maharashtra : 402302 <BR>Tel: 91-2145-233427 <BR>Email: caprolactumcl@gmail.com <BR>Website: http://www.caprolactam.co.in

Are Caprolactam Chemicals Ltd latest results good or bad?

Caprolactam Chemicals Ltd's latest Q4 FY26 results are strong, with a net profit of ₹0.84 crores, a 90.48% increase quarter-on-quarter, and significant revenue growth. However, concerns about high valuation and lack of institutional interest may impact long-term stability.

Caprolactam Chemicals Ltd's latest results for Q4 FY26 indicate a strong performance, showcasing significant improvements across various financial metrics. The company reported a net profit of ₹0.84 crores, which is a remarkable 90.48% increase quarter-on-quarter and a return to profitability compared to the same quarter last year. Revenue also saw substantial growth, increasing by 90.68% year-on-year and 19.92% quarter-on-quarter, reaching ₹3.07 crores.<BR><BR>The operating margin has expanded to 54.07%, the highest in eight quarters, reflecting effective cost management and operational efficiency. Additionally, the profit after tax (PAT) margin improved to 27.36%, a significant recovery from a negative margin in the previous year.<BR><BR>Overall, these results suggest a positive turnaround for Caprolactam Chemicals, indicating that the company is on a recovery path after previous challenges. However, while the operational metrics are encouraging, there are concerns regarding the company's high valuation relative to its earnings and the absence of institutional investor interest, which could affect its long-term stability.

Is Caprolactam Chem overvalued or undervalued?

As of November 28, 2025, Caprolactam Chem is considered overvalued with a high PE ratio of 2771.50 and other metrics significantly above industry norms, making it a less prudent investment despite a recent 20.14% stock return.

As of 28 November 2025, the valuation grade for Caprolactam Chem has moved from fair to expensive, indicating a shift in perceived value. The company is currently overvalued based on its high PE ratio of 2771.50, a price to book value of 5.21, and an EV to EBITDA of 15.28, which are significantly higher than industry norms. <BR><BR>In comparison, peers such as Sun Pharma have a PE ratio of 38.03 and an EV to EBITDA of 25.17, while Cipla, which is considered attractive, has a PE ratio of 22.71 and an EV to EBITDA of 16.07. The stark contrast in these ratios suggests that Caprolactam Chem is not only overvalued relative to its peers but also lacks the financial performance metrics that would justify such a high valuation. Despite recent strong stock performance, with a one-year return of 20.14% compared to the Sensex's 8.43%, the underlying valuation metrics indicate that the stock is not a prudent investment at its current price.

How has been the historical performance of Caprolactam Chem?

Caprolactam Chem has experienced significant declines in net sales and profitability, with net sales dropping from 9.84 Cr in March 2023 to 6.74 Cr in March 2025, and profit after tax turning negative at -0.71 Cr. The company faces ongoing financial difficulties, reflected in increased liabilities and stagnant cash flow.

Answer:<BR>The historical performance of Caprolactam Chem has shown significant fluctuations over the years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Caprolactam Chem's net sales peaked at 9.84 Cr in March 2023 but have since declined to 6.74 Cr by March 2025. The total operating income followed a similar trend, dropping from 9.84 Cr in March 2023 to 6.74 Cr in March 2025. The company faced challenges with operating profit, which reached a high of 4.67 Cr in March 2023 but fell to 1.54 Cr by March 2025. Profit before tax also turned negative in March 2025 at -0.68 Cr, contrasting with a profit of 2.97 Cr in March 2023. Consequently, profit after tax reflected a loss of -0.71 Cr in March 2025, down from a profit of 2.55 Cr in March 2023. The company's total liabilities increased from 11.52 Cr in March 2023 to 14.28 Cr in March 2025, while total assets rose slightly from 11.52 Cr to 14.28 Cr in the same period. Cash flow from operating activities remained stagnant, with no cash inflow reported in March 2025, indicating ongoing financial difficulties. Overall, Caprolactam Chem has experienced a decline in sales and profitability, leading to a challenging financial position in recent years.

When is the next results date for Caprolactam Chem?

Caprolactam Chem will announce its results on 14 August 2025.

Caprolactam Chem will declare its results on 14 August 2025.

Who are the top shareholders of the Caprolactam Chem?

The top shareholders of Caprolactam Chem include Siddharth Shankarlal Bhanushali with 22.98%, and individual investors who hold 43.84% of the shares. There are no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Caprolactam Chem primarily consist of its promoters, with Siddharth Shankarlal Bhanushali holding the largest share at 22.98%. Additionally, individual investors collectively hold 43.84% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

What is the technical trend for Caprolactam Chem?

As of June 6, 2025, Caprolactam Chem's technical trend is mildly bearish, supported by bearish MACD and moving averages, despite a mildly bullish KST signal on the weekly chart.

As of 6 June 2025, the technical trend for Caprolactam Chem has changed from bearish to mildly bearish. The weekly MACD remains bearish, and the monthly MACD is also bearish, indicating ongoing downward momentum. The Bollinger Bands are bearish on both weekly and monthly time frames, reinforcing the negative outlook. Daily moving averages are bearish, suggesting short-term weakness. The KST shows a mildly bullish signal on the weekly chart, but the monthly remains bearish, indicating mixed signals. Dow Theory indicates a mildly bearish stance on the weekly chart, with no clear trend on the monthly. Overall, the current technical stance is mildly bearish, driven primarily by the bearish MACD and moving averages.

Has Caprolactam Chem declared dividend?

No Dividend History Available